Invesaro

Stocks Health care RDGL

OTC · Health care

Vivos Inc (RDGL)

Vivos Inc brought in $99.1K of revenue over the twelve months to June 30, 2026, up 91.5% from a year earlier. It posted a net loss of $3.6M. In fiscal 2025 capital spending exceeded operating cash flow by $2.2M. At June 30, 2026 it held $2.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch RDGL in 60 seconds
Price
$0.05
-1.67% on the day · September 25, 2026
52-week range $0.04 to $0.12
Market cap
$22.7M
Revenue (last 12 months)
$99.1K
+91.5% year on year
Net margin
-3,633.6%

What Vivos Inc does

Vivos Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker RDGL.

Revenue and profit by year

Revenue
FY19: $9.5K $9.5K FY19FY20: $7K $7K FY20FY21: $14.9K $14.9K FY21FY22: $36.5K $36.5K FY22FY23: $19.5K $19.5K FY23FY24: $28K $28K FY24FY25: $68.4K $68.4K FY25
Net income
FY18: -$7.7M -$7.7M FY18FY19: -$1.6M -$1.6M FY19FY20: -$957K -$957K FY20FY21: -$2.5M -$2.5M FY21FY22: -$2.5M -$2.5M FY22FY23: -$2.9M -$2.9M FY23FY24: -$2.9M -$2.9M FY24FY25: -$3.1M -$3.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$68.4K-$3.2M-$3.1M-$0.01-$2.2M
2024$28K-$2.6M-$2.9M-$0.01n/a
2023$19.5K-$2.8M-$2.9M-$0.01n/a
2022$36.5K-$2.5M-$2.5M-$0.01n/a
2021$14.9K-$2.5M-$2.5M-$0.01n/a
2020$7K-$672.5K-$957K$0.00n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 11, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 12, 2025. Not a date the company has announced. See the report calendar

Where RDGL ranks in Health care

Revenue$68.4K
#711 of 742 in Health care · Bottom 4%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Vivos Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 12, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 143% to $36.4K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  2. May 14, 2026
    Quarterly report 10-Q · period to March 31, 2026Revenue rose 35% to $36.1K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  3. March 31, 2026
    Annual report 10-K · period to December 31, 2025Revenue rose 144% to $68.4K versus the prior year; diluted EPS -$0.01 versus -$0.01.
  4. March 5, 2026
  5. March 4, 2026
  6. February 17, 2026
  7. November 12, 2025
    Quarterly report 10-Q · period to September 30, 2025Revenue fell 62% to $1.9K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  8. September 24, 2025
  9. September 22, 2025
  10. September 18, 2025

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 16, 2026. Insider transactions on SEC

Insider trades

What the people running Vivos Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $37.6K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)
$37.6K
last 90 days
Sold
$0
last 90 days
Net bought
637,550
$37.6K
DateInsiderWhatSharesPriceValueFiling
September 16, 2026 Weeks Brad AllanPresident Bought 25,550 $0.05 $1.2K Form 4
August 10, 2026 Korenko Michael KCEO AND PRESIDENT, Director Bought 150,000 $0.05 $8K Form 4
August 10, 2026 Weeks Brad AllanPresident Bought 50,000 $0.05 $2.7K Form 4
July 22, 2026 Weeks Brad AllanPresident Bought 32,000 $0.05 $1.6K Form 4
July 21, 2026 Weeks Brad AllanPresident Bought 60,000 $0.05 $3K Form 4
July 15, 2026 Korenko Michael KCEO AND PRESIDENT, Director Bought 200,000 $0.06 $11.4K Form 4
July 10, 2026 Weeks Brad AllanPresident Bought 12,000 $0.08 $960 Form 4
July 10, 2026 Weeks Brad AllanPresident Bought 12,000 $0.08 $960 Form 4
July 9, 2026 Weeks Brad AllanPresident Bought 48,000 $0.08 $3.8K Form 4
July 9, 2026 Weeks Brad AllanPresident Bought 48,000 $0.08 $3.8K Form 4
June 30, 2026 Weeks Brad AllanPresident Received as pay 147,159 - - Form 4
May 11, 2026 Korenko Michael KCEO AND PRESIDENT, Director Bought 150,000 $0.06 $9.3K Form 4
March 31, 2026 Weeks Brad AllanPresident Received as pay 100,111 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns RDGL

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 12,982,294 shares in total, about $595.9K at the last price.

HolderSharesAs of
Korenko Michael KCEO AND PRESIDENT, Director 11,435,090 August 10, 2026
Weeks Brad AllanPresident 1,547,204 September 16, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RDGL

What does Vivos Inc do?

Vivos Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker RDGL.

Is Vivos Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $3.6M on revenue of $99.1K.

How much revenue does Vivos Inc make?

Over the twelve months to June 30, 2026 Vivos Inc reported revenue of $99.1K. That is 91.5% more than a year earlier.

When did Vivos Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 16, 2026.

Similar companies

Compare RDGL with

Compare RDGL with any company

Follow RDGL

Get an email when Vivos Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow RDGL: get an email when it files

Where the numbers come from

Financial figures are the values Vivos Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.